TY - JOUR AU - Maurel, Joan AU - Lopez-Pousa, Antonio AU - Calabuig, Silvia AU - Bague, Silvia AU - Garcia-Del-Muro, Xavier AU - Sanjuan, Xavier AU - Rubio-Casadevall, Jordi AU - Cuatrecasas, Miriam AU - Martinez-Trufero, Javier AU - Horndler, Carlos AU - Fra, Joaquin AU - Valverde, Claudia AU - Redondo, Andres AU - Poveda, Andres AU - Sevilla, Isabel AU - Lainez, Nuria AU - Rubini, Michele AU - Garcia-Albeniz, Xabier AU - Martin-Broto, Javier AU - de-Alava, Enrique PY - 2016 DO - 10.1186/s13569-016-0050-6 SN - 2045-3329 UR - https://hdl.handle.net/10668/27773 T2 - Clinical sarcoma research AB - Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, PDGFRA mutation or WT for KIT and PDGFRA have a worse progression-free survival (PFS) compared to patients with KIT exon 11 mutated tumors. We evaluated the... LA - en PB - BioMed Central KW - Progression-Free Survival KW - Matrix Metalloproteinase 3 KW - Paraffin Embedding KW - Gastrointestinal Stromal Tumors KW - Receptor Protein-Tyrosine Kinases KW - Exons KW - DNA KW - Mutation KW - Genotype KW - Polymerase Chain Reaction TI - Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. TY - research article VL - 6 ER -